Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

GHRP-2

A strong GH-releaser that works through the hunger-hormone (ghrelin) receptor. Hits GH harder than Ipamorelin, with less appetite than GHRP-6; pairs with a GHRH like Sermorelin/CJC for a bigger combined pulse.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

A strong GH-releaser that works through the hunger-hormone (ghrelin) receptor.

Hits GH harder than Ipamorelin, with less appetite than GHRP-6; pairs with a GHRH like Sermorelin/CJC for a bigger combined pulse.

What It Does

GHRP-2 (pralmorelin) is a ghrelin-mimetic GH secretagogue (GHS-R1a agonist).

It amplifies the GH pulse and, combined with a GHRH analog, produces a markedly larger release than either alone.

Mildly raises cortisol and prolactin and stimulates appetite, less than GHRP-6, more than Ipamorelin.

Reconstitution

Vial SizeBAC Water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
15 mg+ 3 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–22×/day100 mcgAM fasted + pre-bed. Start low; assess flushing and tolerance.
Weeks 3–122–3×/day200 mcgWorking dose. ~1 mcg/kg per dose is the saturating range, more raises cortisol/prolactin without more GH.
Off4 weeks–Prevents ghrelin-receptor downregulation.
Cycle & Timing

8–12 weeks on / 4 weeks off.

Timing

Empty stomach, no food 30 min after, ideally 2–3 h since last meal. Carbs/fats blunt the pulse. Pair each dose with a GHRH for synergy. Saturation: dose plateaus ~1 mcg/kg; going higher mostly adds cortisol/prolactin.

Population Considerations

Women need more GH but get a bigger bump from ghrelin-types, though these raise prolactin, which can disrupt cycles/ovulation (watch for missed periods). Oral estrogen blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal); high prolactin lowers libido and testosterone, switch to a cleaner option if it cli Women need more GH but get a bigger bump from ghrelin-types, though these raise prolactin, which can disrupt cycles/ovulation (watch for missed periods). Oral estrogen blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal); high prolactin lowers libido and testosterone, switch to a cleaner option if it climbs.

Handling & Stacking

Injection site
SubQ, abdomen. Rotate.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~3–4 weeks (inferred from a marketed analog).
Side effects
Flushing/warmth, mild appetite increase, water retention, occasional prolactin/cortisol bump (rarely tingling nipples). Less hunger than GHRP-6.
What to expect
  • Improved sleep and recovery within 1–2 weeks; body-composition changes over 8–12 weeks.
  • Strongest as part of a GHRH + GHRP stack.
  • Supply math 5mg → 7 vials | 10mg → 4 vials | 15mg → 3 vials (12-wk @ 200 mcg × 2/day)
Pairs well with
CJC-1295 (No DAC) / Sermorelin (canonical GHRH + GHRP synergy); Ipamorelin (alternate cleaner GHRP); Wolverine Blend (BPC-157 + TB-500)
Avoid
Active malignancy. Severe insulin resistance. Elevated baseline prolactin. Stacking multiple GHRPs at once
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label) Pregnancy and lactation
Warnings
Insulin resistance / worsening glycemic control with sustained use Cortisol and prolactin elevation (more than Ipamorelin), keep doses near the saturating ~1 mcg/kg Fluid retention, carpal tunnel, joint pain with extended use IGF-1 elevation: theoretical malignancy promotion beyond physiological ranges Combined GHRH+GHRP use requires off cycles to prevent desensitization
Drug interactions
Glucocorticoids: blunt GH response, time away from injection Insulin / antidiabetics: GH worsens insulin resistance, monitor glucose Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1; dopamine agonists may offset prolactin rise
Labs
  • IGF-1 (baseline + Week 8 + end).
  • Target upper-normal for age Fasting glucose / HbA1c (baseline + end) Prolactin if symptomatic (galactorrhea, low libido) Age-appropriate cancer screening before starting Out of range?
  • IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
Stop criteria
Fasting glucose rises >20 mg/dL above baseline IGF-1 above upper limit of normal for age New persistent joint pain or carpal tunnel symptoms Galactorrhea or persistent prolactin symptoms; vision changes
Patient education
Stimulates your own GH, effects build over weeks Keep doses near the saturating range; more is not better and raises cortisol/prolactin Fasted dosing; protect sleep, the largest pulse is at night Not for use during active malignancy or pregnancy; report new lumps or vision changes
References
researchdosing · peptidedosages · PubMed · thepeptidereport · Span 2000 · Weissberger 1991